POAI - Predictive Oncology Inc
Predictive Oncology Inc Logo

POAI - Predictive Oncology Inc

https://predictive-oncology.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Benzinga • 3 weeks, 5 days ago • score: 0.30
NEW ORLEANS, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ( "KSF" ) are investigating the proposed sale of Predictive Oncology Inc. POAI to Renovaro Inc.
Bullish
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
GlobeNewswire • 2 months, 1 week ago • score: 0.28
PITTSBURGH, July 08, 2025 ( GLOBE NEWSWIRE ) -- Predictive Oncology Inc. ( NASDAQ: POAI ) , a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement ( "SEPA" ) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, ...
Bullish
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - Renovaro ( NASDAQ:RENB ) , Predictive Oncology ( NASDAQ:POAI )
Benzinga • 3 months, 3 weeks ago • score: 0.36
LOS ANGELES, May 22, 2025 ( GLOBE NEWSWIRE ) -- Renovaro Inc. RENB, a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, ...
Bullish
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - Renovaro ( NASDAQ:RENB ) , Predictive Oncology ( NASDAQ:POAI )
Benzinga • 3 months, 3 weeks ago • score: 0.36
LOS ANGELES, May 22, 2025 ( GLOBE NEWSWIRE ) -- Renovaro Inc. RENB, a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Predictive Oncology Inc. offers a variety of health care products and services primarily in the United States. The company is headquartered in Eagan, Minnesota.

52W High
$2.25
52W Low
$0.55
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.37
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.51
EV/Revenue (<3 favorable)
6.88
P/S (TTM) (<3 favorable)
5.92
P/B (<3 favorable)
1.43
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.99%
Institutions (25–75% balanced)
1.59%
Shares Outstanding
10,892,700
Float
10,779,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
1,664,700
Gross Profit (TTM)
811,510
EPS (TTM)
-1.13
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-991.75%
ROE (TTM) (>15% strong)
-7.46%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.96
Momentum
Bearish momentum
Value
0.0382
Previous
0.0397
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025